Biomarker Menu
Biomarker Menu

Explore Our Biomarker Menu

Including 400+ Biomarker Offerings for a Range of Disease States

Return to Biomarker Menu

Biomarker: RPA-1

Search for Biomarkers

Analyte:

RPA-1

Platform:

Matrix:

Rat Urine

Disease State:

Toxicity

Status:

Experienced Running

Sensitivity-LLOQ/ULOQ:

LLOQ: 3.6 ng/mL
ULOQ: 880 ng/mL

Biological or Clinical Significance:

Replication protein A 70 kDa DNA-binding subunit is a protein that in humans is encoded by the RPA1 gene. Diseases associated with RPA1 include xeroderma pigmentosum, group a and atrophic rhinitis. Among its related pathways are Cell Cycle, Mitotic and Transport to the Golgi and subsequent modification.

As part of the heterotrimeric replication protein A complex (RPA/RP-A), binds and stabilizes single-stranded DNA intermediates, that form during DNA replication or upon DNA stress. It prevents their reannealing and in parallel, recruits and activates different proteins and complexes involved in DNA metabolism. Thereby, it plays an essential role both in DNA replication and the cellular response to DNA damage. In the cellular respone to DNA damage, the RPA complex controls DNA repair and DNA damage checkpoint activation.

References:

Speak to a Scientist

















What would you like to discuss?

With whom will we be speaking?






I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

Yes I confirm that I am over the age of 16 and I consent to communications from BioAgilytix.


biomarker services

Services

See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.

Explore our services

case studies

Case Studies

Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.

Read our case studies